These studies showed that IFN-α suppresses the proliferation of all type I IFN receptor type 2 (IFNAR2)-positive cancer cell lines in vitro, and that the expression of IFNAR2 in HCC tissues was significantly associated with clinical response to the IFN-α/5-FU combination therapy. Here, IFNA1 is linked to hepatocellular carcinoma.